Policy & Pharma
White House–Regeneron drug pricing deal
What's happening
The White House is set to announce a drug pricing agreement with Regeneron Pharmaceuticals today. As part of the "most-favored-nation" initiative, Regeneron will lower prices for current and future drugs on Medicaid and offer its cholesterol drug, Praluent, for $225 on the discounted drug website TrumpRx.
What's changing / Business impact
-
Government is pushing direct pricing negotiations with pharma.
-
Signals continued expansion of: price control mechanisms and negotiation frameworks.
-
Pharma companies face increasing pressure on margins.
Why this matters
Drug pricing is one of the most powerful levers in U.S. healthcare.
This shows:
-
Policy is shifting from passive regulation → active negotiation.
-
Pricing power is moving away from pharma toward government influence.
-
Future revenue models will depend on policy alignment, not just innovation.